EVAX Stock Analysis: Buy, Sell, or Hold?
EVAX - Evaxion A/S American Depositary Share
$3.64
0.03 (0.83%)
▲
5d:
+2.54%
30d:
-12.5%
90d:
-14.55%
HOLD
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Get Alerted When EVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EVAX is fairly valued with market pricing in 0.9% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: EVAX is fairly valued with market pricing in 0.9% annual growth. Fine to hold or accumulate slowly on dips.
In-depth Analysis How we analyze
Valuation Analysis: EVAX is currently trading at $3.64, which is considered oversold relative to its 30-day fair value range of $3.72 to $4.16. The stock's valuation (Forward PE: 91.0) is in line with its historical norms (88.5). At these levels, the market is pricing in 0.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, EVAX is in a uptrend. Immediate support is located at $3.42, while resistance sits at $4.23.
Market Sentiment: EVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.25 (+209.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EVAX is in a uptrend. Immediate support is located at $3.42, while resistance sits at $4.23.
Market Sentiment: EVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $11.25 (+209.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.72 -
$4.16
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 209.1% below Wall St target ($11.25)
- NEUTRAL: Market pricing in 0.9% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$3.72 -
$4.16
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.42
Resistance Level
$4.23
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
91.00
Wall Street Target
$11.25
(+209.1%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-129.6%
Valuation Premium vs History
+0.9% premium
PE vs Historical
91.0 vs 88.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.9%
(market-implied from PE analysis)
1-Year Target
$3.67
(+1%)
2-Year Target
$3.71
(+2%)
3-Year Target
$3.74
(+3%)
3-Yr Target (if PE normalizes)
(PE: 91→89)
PE COMPRESSION
$3.64
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 15, 2026 8:25 AM ET
Data refreshes hourly during market hours. Next update: 9:25 AM
Data refreshes hourly during market hours. Next update: 9:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$275 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 59 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 54 HOLD |